Assessing an enoxaparin dosing protocol in morbidly obese patients

Journal of Thrombosis and Thrombolysis

Volumn 39, Issue 4, 2015, Pages 516-521

  Lalama, Jeffrey T ^a,b   Feeney, Megan E ^a   Vandiver, Jeremy W ^b,c   Beavers, K Diane ^b   Walter, Leah N ^b   McClintic, Jacqueline R ^b  

^a REGIS UNIVERSITY   (United States)

^b SWEDISH MEDICAL CENTER   (United States)

^c UNIVERSITY OF WYOMING SCHOOL OF PHARMACY   (United States)

Author keywords

Anti Xa monitoring; Anticoagulation; Enoxaparin; Obesity

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN;

ADULT; AGED; BLOOD; BODY MASS; FEMALE; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; OBESITY, MORBID; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; ENOXAPARIN; FACTOR XA INHIBITORS; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; OBESITY, MORBID; RETROSPECTIVE STUDIES;

EID: 84939881479     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-014-1117-y     Document Type: Article

References (15)

1. Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49(2):71–87
2. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE (2009) s. Ann Pharmacother 43(6):1064–1083
3. Product Information. Lovenox (enoxaparin sodium injection). Bridgewater, NJ: sanofi-aventis US LLC, May 2007
4. Holbrook A, Schulman S, Witt DM et al (2012) Evidence-based management of anticoagulant therapy: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e152S–e184S
5. Spinler SA, Inverso SM, Cohen M et al (2003) Safety and Efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 146:33–41
6. Deal EN, Hollands JM, Riney JN, Skrupky LP, Smith JR, Reichley RM (2011) Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series. J Thromb Thrombolysis 32(2):188–194
7. Clark NP (2008) Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency. Thromb Res 123(Suppl 1):S58–S61
8. The Gusto Investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329(10):673–682
9. Bazinet A, Almanric K, Brunet C et al (2005) Dosage of enoxaparin among obese and renal impairment patients. ThrombRes. 116(1):41–50
10. Levine L, Pallme N, Angelotti E, Shiltz D (2013) Analysis of anti-Xa concentrations in patients on treatment dose enoxaparin: a retrospective chart review. Adv Pharmacol Pharm 1(2):37–41
11. Spinler SA, Ou FS, Roe MT et al (2009) Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative. Pharmacotherapy 29(6):631–638
12. Niewenhuis HK, Albada J, Banga JD et al (1991) Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular heparin. Blood 78:2337–2343
13. Hagopian JC, Riney JN, Hollands JM, Deal EN (2013) Assessment of bleeding events associated with short-duration therapeutic enoxaparin use in the morbidly obese. Ann Pharmacother 47(12):1641–1648
14. Montalescot G (2004) Collet JP, Tanguy ML, e al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 110:392–398
15. Garcia DA, Baglin TP, Weitz JI, Samama MM (2012) Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e24S–e43S